Evidence map›Paper›PMID 34842275›Full record

ArticleBiology open2021

Vitamin A cycle byproducts explain retinal damage and molecular changes thought to initiate retinal degeneration.

Dan Zhang, Doina M Mihai, Ilyas Washington

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dan ZhangColumbia University Medical Center, Ophthalmology, New York, NY 10032, USA.
Doina M MihaiColumbia University Medical Center, Ophthalmology, New York, NY 10032, USA.
Ilyas WashingtonColumbia University Medical Center, Ophthalmology, New York, NY 10032, USA.ORCID 0000-0002-2238-7918
Columbia University Irving Medical Center · US

Funding

The role and mechanisms of lipofuscin formation in macular degenerationR01EY021207 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WASHINGTON, ILYAS · 2011 to 2015
$1.9M
NEI NIH HHS R01 EY021207
6 · The paper itself

Abstract

In the most prevalent retinal diseases, including Stargardt disease and age-related macular degeneration (AMD), byproducts of vitamin A form in the retina abnormally during the vitamin A cycle. Despite evidence of their toxicity, whether these vitamin A cycle byproducts contribute to retinal disease, are symptoms, beneficial, or benign has been debated. We delivered a representative vitamin A byproduct, A2E, to the rat's retina and monitored electrophysiological, histological, proteomic, and transcriptomic changes. We show that the vitamin A cycle byproduct is sufficient alone to damage the RPE, photoreceptor inner and outer segments, and the outer plexiform layer, cause the formation of sub-retinal debris, alter transcription and protein synthesis, and diminish retinal function. The presented data are consistent with the theory that the formation of vitamin A byproducts during the vitamin A cycle is neither benign nor beneficial but may be sufficient alone to cause the most prevalent forms of retinal disease. Retarding the formation of vitamin A byproducts could potentially address the root cause of several retinal diseases to eliminate the threat of irreversible blindness for millions of people.

Indexed as

AnimalsDisease Models, AnimalMacular DegenerationRatsRetinaRetinal DegenerationRetinal Pigment EpitheliumRetinoidsVitamin AA2-E (N-retinylidene-N-retinylethanolamine)RetinoidsVitamin AA2EAge-related macular degenerationRetinaStargardt diseaseVitamin A

Identifiers

PMID34842275
PMCPMC8649638
OpenAlexW3216204455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.